lipid specialists s.c The newly released 2026 ACC/AHA Dyslipidemia Guideline (published March 13, 2026) marks a definitive shift toward more aggressive, individualized management. Key Clinical Updates: • Target-Based Care: Return to absolute LDL-C goals The Role of Lipids and

On July 23-24, 2026 , the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene at the FDA White Oak Campus (10903 New Hampshire Avenue, Silver Spring, MD 20993) to evaluate whether several peptides should be added to the Section 503A bulk drug substances list

Response: Reporting on this measure will continue to be voluntary, and as such HOPDs can determine their readiness to implement any changes necessary if they elect to report on this measure

Most patients notice improvements in energy, mood, and other symptoms soon after beginning treatment

Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1)